Collegium Pharmaceutical, Inc.

Greetings and welcome to the Collegium Pharmaceutical fourth quarter 2020 earnings call. At this time, all participants earn a listen-only mode. A brief question and answer session will follow formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Alex DeSala. Head of Investor Relations for Collegium. Thank you, Ms. Dasala, you may begin.

Welcome to Collegium Pharmaceutical's fourth quarter 2020 earnings conference call. This is Alex Dasala, Head of Investor Relations for Collegium. I am joined today by Joe Schifoni, our Chief Executive Officer, Paul Branley, our Chief Financial Officer, and Scott Dreyer, our Chief Commercial Officer. Before we begin today's call, we want to remind participants Thank you for joining us today. In current or future opioid industry litigation and investigations, patent infringement litigation, or other litigation pertaining to our products. These risks and other risks of the company are detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at collegiumpharma.com. I will now turn the call over to Collegium CEO, Joe Schifoni.

Thank you, Alex. Good afternoon and thank you everyone for joining the call. I'm pleased to be here today to discuss our Q4 and year-end 2020 performance, as well as our 2021 outlook. As you know, Collegium is committed to our mission of being the leader in responsible pain management and is highly dedicated to people living with pain in the communities we serve. We are focused on executing our strategy with dual aims of delivering on our mission and creating value for our shareholders. We do this through maximizing the value of our differentiated pain portfolio, achieving our near-term operational and financial goals and strategically investing in our long-term growth, including investments in our people, Thank you for joining us today. Key accomplishments in 2020 include achieving Collegium's first full year of profitability and growing revenue in the face of COVID-19, accelerating Xtamsa ER growth, notably strengthening formulary positions and securing the path to market leadership in 2023, executing the Nucenta franchise transaction, completing construction and validation of the dedicated facility for Xtamsa ER, Making It Commercially Operational, Settling the Teva-Extamsa ER and the Litigation, which contemplates a generic launch no earlier than September 2033 and confirms the strength of the Extamsa ER patent estate, and importantly, supporting our communities and committing as an organization to acting in a socially responsible manner. This includes our partnership with Life Science Cares, and many more. and thank them for their commitment to people living with pain and communities we serve. Looking ahead to 2021, we are encouraged by the early trends. Our business is strong and our people are healthy. I'd also like to note that Collegium was recently recognized as a 2021 Top Workplaces USA company, a testament to our mission, core values and culture. We are entering a phase of growth and value creation and we will continue to look for opportunities to maximize the value of our differentiated pain portfolio and strategically invest in the long-term growth of our company. I'm confident that we have the right plan and more importantly people in place to make it happen. I look forward to updating you on our progress throughout 2021. I will now hand the call over to Paul for a discussion of the financials.